Welcome to our dedicated page for Sofgen Pharma S.A. SEC filings (Ticker: PROCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Sofgen Pharma S.A.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Sofgen Pharma S.A.'s regulatory disclosures and financial reporting.
Sofgen Pharma S.A. filed an initial Form 3 for Chief Commercial Officer Luis Alberto Palacios. This filing identifies him as an officer and reporting person for Sofgen Pharma’s securities but does not report any transactions or derivative positions. It establishes his status for future ownership disclosures.
Sofgen Pharma S.A. filed an initial ownership report for director Carlos Garcia Iragorri. This Form 3 shows his status as a director of the company but does not list any share transactions or derivative positions. The summarized data indicate no reported purchases, sales, exercises, gifts, or other changes in ownership at this time.
Sofgen Pharma S.A. director and 10% owner Fernando Sebastian Moreira Muniz filed an initial statement of beneficial ownership. The filing reports indirect holdings through Becaril S.A., which Becaril beneficially owns 305,309,149 Ordinary Shares of Sofgen Pharma and a warrant to purchase 19,800,411 Ordinary Shares with an exercise price of $0.0631 per share expiring on April 9, 2035. These entries reflect existing positions rather than new market transactions.
Sofgen Pharma S.A. director Manuel Jose Vial Claro filed an initial ownership report on Form 3. The filing establishes his status as a reporting person and shows no reported purchases, sales, or other transactions, with all transaction counts and share amounts indicated as zero.
Sofgen Pharma S.A. director and 10% owner Manieu Alexandre Weinstein filed an initial Form 3 that reports large indirect holdings in the company through Hoche Partners Pharma Holdings LLC. The filing shows indirect ownership of 626,495,816 Ordinary Shares and a warrant to purchase 79,201,647 Ordinary Shares.
The warrant has an exercise price of $0.0631 per Ordinary Share and expires on April 9, 2035. Both the Ordinary Shares and the warrant are beneficially owned by Hoche Partners Pharma Holdings LLC, an entity controlled by Mr. Weinstein, and this filing reflects holdings rather than new market transactions.
Sofgen Pharma S.A. filed an initial ownership report for Interim CEO Melissa Andreia Silva Angelini. This Form 3 does not list any equity transactions or derivative holdings, and the summary data shows no reported purchases, sales, exercises, gifts, or restructurings.
Sofgen Pharma S.A. director Nicolas Alexandre Weinstein has filed a Form 3, which is an initial statement of beneficial ownership for insiders. This filing identifies him as a director of the company and establishes his insider reporting status, but does not list any transactions.
Sofgen Pharma S.A. submitted a Form 15 certifying termination of registration under Section 12(g) of the Securities Exchange Act of 1934, effective by the filing dated March 16, 2026. The notice lists Ordinary shares (nominal $0.01) and Warrants exercisable at $11.50 as the classes covered, and shows 80 holders of the ordinary shares and 44 holders of the warrants.
Sofgen Pharma S.A. files its Form 20-F annual report for the year ended December 31, 2024, outlining its business, risks and capital structure. The company reports 112,824,184 Ordinary Shares and 23,375,000 Warrants outstanding as of December 31, 2024 and total indebtedness of $268.0 million. Auditors include a going concern emphasis, reflecting covenant breaches and reliance on forbearance agreements with lenders. The filing details multiple material weaknesses in internal control over financial reporting and extensive remediation efforts. Sofgen also describes its delisting from Nasdaq, current trading on the OTC Expert Market, and broad operational, regulatory, supply chain, technology, macroeconomic and tax risks affecting its pharmaceutical and iCDMO businesses.